For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyngeal carcinoma has been mainly empirical. To our
<正>Despite all the human efforts and monetary investment over the last few decades,cancer is still a devastating threat to our life expectancy and quality of l